BridgeBio Submits NDA for LGMD2I/R9 Drug

BridgeBio has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for BBP-418, a treatment for individuals diagnosed with Limb-Girdle Muscular Dystrophy type 2I/R9. The submission is supported by interim data from the Phase 3 FORTIFY trial. This data highlights BBP-418's ability to deliver rapid and consistent therapeutic effects, alongside a favorable safety profile. The company is seeking approval to bring this potentially life-changing therapy to patients suffering from this rare genetic disorder, aiming to address a significant unmet medical need in the muscular dystrophy landscape.